These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
394 related articles for article (PubMed ID: 22064247)
1. Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer. Wang ZX; Xue D; Liu ZL; Lu BB; Bian HB; Pan X; Yin YM Int J Biochem Cell Biol; 2012 Jan; 44(1):200-10. PubMed ID: 22064247 [TBL] [Abstract][Full Text] [Related]
2. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo. Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676 [TBL] [Abstract][Full Text] [Related]
3. Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma. Cheng MW; Wang BC; Weng ZQ; Zhu XW Acta Histochem; 2012 Sep; 114(5):503-9. PubMed ID: 22000864 [TBL] [Abstract][Full Text] [Related]
4. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments]. Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094 [TBL] [Abstract][Full Text] [Related]
5. [Effect of antisense RNA targeting Polo-like kinase 1 on cell cycle of lung cancer cell line A549]. Zhou Q; Bai M; Su Y Ai Zheng; 2005 Feb; 24(2):149-54. PubMed ID: 15694023 [TBL] [Abstract][Full Text] [Related]
6. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Rudolph D; Steegmaier M; Hoffmann M; Grauert M; Baum A; Quant J; Haslinger C; Garin-Chesa P; Adolf GR Clin Cancer Res; 2009 May; 15(9):3094-102. PubMed ID: 19383823 [TBL] [Abstract][Full Text] [Related]
7. E1AF/PEA3 activates the Rho/Rho-associated kinase pathway to increase the malignancy potential of non-small-cell lung cancer cells. Hakuma N; Kinoshita I; Shimizu Y; Yamazaki K; Yoshida K; Nishimura M; Dosaka-Akita H Cancer Res; 2005 Dec; 65(23):10776-82. PubMed ID: 16322223 [TBL] [Abstract][Full Text] [Related]
8. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Zhang W; Chen Y; Wei H; Zheng C; Sun R; Zhang J; Tian Z Clin Cancer Res; 2008 Oct; 14(20):6432-9. PubMed ID: 18927282 [TBL] [Abstract][Full Text] [Related]
9. Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Vicent S; Garayoa M; López-Picazo JM; Lozano MD; Toledo G; Thunnissen FB; Manzano RG; Montuenga LM Clin Cancer Res; 2004 Jun; 10(11):3639-49. PubMed ID: 15173070 [TBL] [Abstract][Full Text] [Related]
10. Polo-like kinase 1 contributes to the tumorigenicity of BEL-7402 hepatoma cells via regulation of Survivin expression. He Z; Wu J; Dang H; Lin H; Zheng H; Zhong D Cancer Lett; 2011 Apr; 303(2):92-8. PubMed ID: 21330050 [TBL] [Abstract][Full Text] [Related]
11. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways. Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174 [TBL] [Abstract][Full Text] [Related]
12. Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas. Jang YJ; Kim YS; Kim WH Int J Oncol; 2006 Sep; 29(3):589-94. PubMed ID: 16865274 [TBL] [Abstract][Full Text] [Related]
13. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets. Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374 [TBL] [Abstract][Full Text] [Related]
14. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells. Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192 [TBL] [Abstract][Full Text] [Related]
15. [Study of growth inhibition of gastric cancer cells by sRNA targeting polo like kinase 1 in vitro and vivo]. Lan B; Liu BY; Cheng XH; Qu Y; Zhang XQ; Cai Q; Dai QB; Zhu ZG Zhonghua Wai Ke Za Zhi; 2006 Jan; 44(1):40-4. PubMed ID: 16620646 [TBL] [Abstract][Full Text] [Related]
16. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells. Bu Y; Yang Z; Li Q; Song F Oncology; 2008; 74(3-4):198-206. PubMed ID: 18714168 [TBL] [Abstract][Full Text] [Related]
17. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Spänkuch-Schmitt B; Wolf G; Solbach C; Loibl S; Knecht R; Stegmüller M; von Minckwitz G; Kaufmann M; Strebhardt K Oncogene; 2002 May; 21(20):3162-71. PubMed ID: 12082631 [TBL] [Abstract][Full Text] [Related]
18. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Gilmartin AG; Bleam MR; Richter MC; Erskine SG; Kruger RG; Madden L; Hassler DF; Smith GK; Gontarek RR; Courtney MP; Sutton D; Diamond MA; Jackson JR; Laquerre SG Cancer Res; 2009 Sep; 69(17):6969-77. PubMed ID: 19690138 [TBL] [Abstract][Full Text] [Related]
19. Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance. Su L; Wang Y; Xiao M; Lin Y; Yu L Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):484-91. PubMed ID: 20868995 [TBL] [Abstract][Full Text] [Related]